Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oncotelic Therapeutics, Inc.MATN · Entity 7822 | CHIEF TECHNOLOGY OFFICER | November 19, 2020 | November 23, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oncotelic Therapeutics, Inc.
Report date November 19, 2020 · Filed November 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,833,992 |
Reported balance
After 2020-11-19 transaction · row 1
1 source rowRow 1 · 2020-11-19 · Purchase · Acquired 22,173 · Balance 2,833,992 F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.183 to $0.185 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.183 to $0.185 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 19, 2020 Filed Nov 23, 2020 20:01 UTC | Oncotelic Therapeutics, Inc. MATN · Entity 7822 | PurchaseCommon Stock | 22,173 | $0.18 | $4,097.57 |
DisclosureSEC source: 0001493152-20-022257 · ownership.xml · nonDerivative · entry 1 Park Chulho · CIK 0001775662 · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,833,992 F1 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.183 to $0.185 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.